BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its price objective increased by stock analysts at Needham & Company LLC from $14.00 to $15.00 in a report issued on Monday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. Needham & Company LLC's price target suggests a potential upside of 89.16% from the stock's current price.

A number of other brokerages have also weighed in on BCRX. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $15.17.

BioCryst Pharmaceuticals Stock Up 3.4 %

NASDAQ:BCRX traded up $0.26 on Monday, hitting $7.93. The stock had a trading volume of 2,651,891 shares, compared to its average volume of 2,470,313. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88. The company has a fifty day moving average price of $7.59 and a two-hundred day moving average price of $7.59. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -13.00 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analysts' expectations of $113.99 million. During the same period in the previous year, the firm earned ($0.19) EPS. The firm's revenue for the quarter was up 35.1% compared to the same quarter last year. As a group, analysts anticipate that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of BCRX. Principal Financial Group Inc. raised its holdings in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock worth $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Exome Asset Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at about $1,493,000. Franklin Resources Inc. increased its holdings in BioCryst Pharmaceuticals by 177.8% during the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock valued at $1,968,000 after acquiring an additional 168,790 shares in the last quarter. Sanctuary Advisors LLC raised its position in BioCryst Pharmaceuticals by 78.3% during the third quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company's stock worth $360,000 after acquiring an additional 20,818 shares during the last quarter. Finally, SkyView Investment Advisors LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.